The GPR171 Knockout A-549 Polyclonal Cells constitute a heterogeneous population of human A-549 lung adenocarcinoma epithelial cells subjected to CRISPR/Cas9-mediated disruption of the GPR171 locus. This polyclonal knockout model enables rigorous investigation of the functional consequences of depleting this orphan G protein-coupled receptor (GPCR), without the clonal biases that can arise in monoclonal knockout cell lines.
Originally established from the lung adenocarcinoma of a 58-year-old male, the A-549 cell line is a widely accepted surrogate for human alveolar type II epithelium. These adherent epithelial cells display lamellar bodies and produce surfactant, characteristics that underscore their utility in lung biology research. Extensively employed to study non-small cell lung cancer (NSCLC) pathobiology, A-549 cells retain malignant features including aberrant proliferative signaling and metabolic adaptations, making them a relevant host for dissecting GPCR contributions to tumorigenesis.
GPR171 is activated by the neuropeptide BigLEN, a proSAAS-derived ligand, and functions primarily through coupling with pertussis toxin-sensitive G??i and G??o proteins. This interaction inhibits adenylyl cyclase, lowering intracellular cAMP levels and diminishing PKA-mediated phosphorylation of the transcription factor CREB. In parallel, GPR171 can signal via ??-arrestin-dependent pathways, assembling MAPK/ERK modules that promote ERK1/2 activation and regulate targets such as Cyclin D1. The receptor also interfaces with PI3K/Akt signaling, influencing cellular survival and metabolism. Additionally, in immunological contexts, GPR171 modulates production of cytokines like interleukin-2 (IL-2) and interferon-?? (IFN-??). G protein-coupled receptor kinases (GRKs) further regulate receptor desensitization and trafficking.
Within the A-549 lung adenocarcinoma background, loss of GPR171 provides a unique platform to assess its impact on cancer hallmarks. Because GPR171 integrates signals from multiple pathways??cAMP/PKA, MAPK/ERK, and PI3K/Akt??its absence may alter cell proliferation, migration, and metabolic programming that fuel NSCLC progression. Moreover, given the receptor??s established role in appetite and energy homeostasis, these knockout cells are invaluable for exploring the intersection between metabolic dysregulation and lung cancer, potentially linking obesity to enhanced tumorigenic potential.
Researchers can deploy this polyclonal knockout model in diverse experimental workflows, including ligand screening for orphan GPCRs, intracellular cAMP assays to quantify Gi/o signaling, and phospho-ERK ELISA for MAPK pathway readouts. The cells are amenable to high-content techniques such as immunofluorescence and flow cytometry to monitor receptor expression and downstream effects, as well as MTT and migration assays to evaluate proliferative and motile phenotypes. Transcriptomic approaches (RNA-seq, RT-qPCR) and western blotting can map GPR171-dependent gene networks and validate alterations in signaling proteins like CREB and Cyclin D1. This product serves as a versatile tool for target validation in lung adenocarcinoma and metabolic disorder research. For detailed data or support, please contact Ascent Research.
